Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine in healthy infants in Japan

Pediatric Infectious Disease Journal

Volumn 32, Issue 9, 2013, Pages 984-989

  Togashi, Takehiro ^a   Yamaji, Masako ^b   Thompson, Allison ^b   Giardina, Peter C ^b   Aizawa, Masakazu ^b   Patterson, Scott ^b   Gruber, William C ^b   Scott, Daniel A ^b  

^a SAPPORO CITY UNIVERSITY   (Japan)

^b PFIZER INC   (United States)

Author keywords

Immunogenicity; Japan; Pediatric; Pneumococcal vaccine; Safety

Indexed keywords

IMMUNOGLOBULIN G; IMMUNOGLOBULIN G ANTIBODY; PNEUMOCOCCUS VACCINE;

ANTIBODY BLOOD LEVEL; ARTICLE; CHILD; CLINICAL EVALUATION; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CUSTODY; DECREASED APPETITE; DISEASE SEVERITY; DRUG SAFETY; DRUG WITHDRAWAL; EXANTHEMA SUBITUM; FEBRILE CONVULSION; FEVER; HUMAN; IMMUNOGENICITY; INFANT; INJECTION SITE ERYTHEMA; INJECTION SITE SWELLING; IRRITABILITY; JAPAN; JAPANESE; MOOD DISORDER; PARENT; PHASE 3 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL (TOPIC); PNEUMOCOCCAL INFECTION; PRIORITY JOURNAL; SEROTYPE; SOMNOLENCE; STANDARD; UPPER RESPIRATORY TRACT INFECTION; URTICARIA;

ANTIBODIES, BACTERIAL; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FEMALE; HUMANS; IMMUNOGLOBULIN G; INFANT; INJECTIONS, SUBCUTANEOUS; JAPAN; MALE; PNEUMOCOCCAL INFECTIONS; PNEUMOCOCCAL VACCINES; STREPTOCOCCUS PNEUMONIAE; VACCINES, CONJUGATE;

EID: 84891626244     PISSN: 08913668     EISSN: 15320987     Source Type: Journal    
DOI: 10.1097/INF.0b013e318293007e     Document Type: Article

References (37)

1. World Health Organization. Estimated Hib and pneumococcal deaths for children under 5 years of age, 2008. 2012. Available at: http://www.who.int/ immunization-monitoring/burden/Pneumo-hib-estimates/en/index.html. Accessed October 17, 2012.
2. Sakata H, Sato Y, Nonoyama M, et al. Results of a multicenter survey of diagnosis and treatment for bacterial meningitis in Japan. J Infect Chemother. 2010;16:396-406.
3. Black S, Shinefield H, Fireman B, et al. Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Northern California Kaiser Permanente Vaccine Study Center Group. Pediatr Infect Dis J. 2000;19:187-195.
4. Eskola J, Kilpi T, Palmu A, et al.; Finnish Otitis Media Study Group. Efficacy of a pneumococcal conjugate vaccine against acute otitis media. N Engl J Med. 2001;344:403-409.
5. Hansen J, Black S, Shinefield H, et al. Effectiveness of heptavalent pneumococcal conjugate vaccine in children younger than 5 years of age for prevention of pneumonia: updated analysis using World Health Organization standardized interpretation of chest radiographs. Pediatr Infect Dis J. 2006;25:779-781.
6. Grijalva CG, Nuorti JP, Arbogast PG, et al. Decline in pneumonia admissions after routine childhood immunization with pneumococcal conjugate vaccine in the USA: a time-series analysis. Lancet. 2007;369:1179-1186.
7. Pilishvili T, Lexau C, Farley MM, et al.; Active Bacterial Core Surveillance/Emerging Infections Program Network. Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine. J Infect Dis. 2010;201:32-41.
8. Vestrheim DF, Løvoll O, Aaberge IS, et al. Effectiveness of a 2+1 dose schedule pneumococcal conjugate vaccination programme on invasive pneumococcal disease among children in Norway. Vaccine. 2008;26:3277-3281.
9. Harboe ZB, Valentiner-Branth P, Benfield TL, et al. Early effectiveness of heptavalent conjugate pneumococcal vaccination on invasive pneumococcal disease after the introduction in the Danish Childhood Immunization Programme. Vaccine. 2010;28:2642-2647.
10. Chiba N, Morozumi M, Sunaoshi K, et al.; IPD Surveillance Study Group. Serotype and antibiotic resistance of isolates from patients with invasive pneumococcal disease in Japan. Epidemiol Infect. 2010;138:61-68.
11. Sakai F, Chiba N, Ono A, et al. Molecular epidemiologic characteristics of Streptococcus pneumoniae isolates from children with meningitis in Japan from 2007 through 2009. J Infect Chemother. 2011;17:334-340.
12. Oishi T, Wada A, Chang B, et al. Serotyping and multilocus sequence typing of Streptococcus pneumoniae isolates from the blood and posterior nares of Japanese children prior to the introduction of 7-valent pneumococcal conjugate vaccine. Jpn J Infect Dis. 2011;64:341-344.
13. Sakata H. Invasive Streptococcus pneumoniae infections in children in Kamikawa and Soya subprefecture, Hokkaido, Japan, 2000-2010, before the introduction of the 7-valent pneumococcal conjugate vaccine. J Infect Chemother. 2011;17:799-802.
14. Kieninger DM, Kueper K, Steul K, et al.; 006 Study Group. Safety, tolerability, and immunologic noninferiority of a 13-valent pneumococcal conjugate vaccine compared to a 7-valent pneumococcal conjugate vaccine given with routine pediatric vaccinations in Germany. Vaccine. 2010;28:4192-4203.
15. Yeh SH, Gurtman A, Hurley DC, et al.; 004 Study Group. Immunogenicity and safety of 13-valent pneumococcal conjugate vaccine in infants and toddlers. Pediatrics. 2010;126:e493-e505.
16. Huang LM, Lin TY, Juergens C. Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine given with routine pediatric vaccines in Taiwan. Vaccine. 2012;30:2054-2059.
17. Bryant KA, Block SL, Baker SA, et al.; PCV13 Infant Study Group. Safety and immunogenicity of a 13-valent pneumococcal conjugate vaccine. Pediatrics. 2010;125:866-875.
18. Snape MD, Klinger CL, Daniels ED, et al. Immunogenicity and reactogenicity of a 13-valent-pneumococcal conjugate vaccine administered at 2, 4, and 12 months of age: a double-blind randomized active-controlled trial. Pediatr Infect Dis J. 2010;29:e80-e90.
19. Esposito S, Tansey S, Thompson A, et al. Safety and immunogenicity of a 13-valent pneumococcal conjugate vaccine compared to those of a 7-valent pneumococcal conjugate vaccine given as a three-dose series with routine vaccines in healthy infants and toddlers. Clin Vaccine Immunol. 2010;17:1017-1026.
20. Vanderkooi OG, Scheifele DW, Girgenti D, et al.; Canadian PCV13 Study Group. Safety and immunogenicity of a 13-valent pneumococcal conjugate vaccine in healthy infants and toddlers given with routine pediatric vaccinations in Canada. Pediatr Infect Dis J. 2012;31:72-77.
21. Kim DS, Shin SH, Lee HJ, et al. Immunogenicity and safety of 13-valent pneumococcal conjugate vaccine given to Korean children receiving routine pediatric vaccines. Pediatr Infect Dis J; 2013;32:266-273.
22. Amdekar YK, Lalwani SK, Tansey SP, et al. Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine in healthy infants and toddlers given with routine vaccines in India. Poster presented at: 48th Annual Meeting of the Infectious Diseases Society of America; October 21-24, 2010; Vancouver, British Columbia, Canada. Abstract 1369.
23. Miller E, Andrews NJ, Waight PA, et al. Effectiveness of the new serotypes in the 13-valent pneumococcal conjugate vaccine. Vaccine. 2011;29:9127-9131.
24. Cohen R, Levy C, Bingen E, et al. Impact of 13-valent pneumococcal conjugate vaccine on pneumococcal nasopharyngeal carriage in children with acute otitis media. Pediatr Infect Dis J. 2012;31:297-301.
25. Wernette CM, Frasch CE, Madore D, et al. Enzyme-linked immunosorbent assay for quantitation of human antibodies to pneumococcal polysaccharides. Clin Diagn Lab Immunol. 2003;10:514-519.
26. Quataert SA, Kirch CS, Wiedl LJ, et al. Assignment of weight-based antibody units to a human antipneumococcal standard reference serum, lot 89-S. Clin Diagn Lab Immunol. 1995;2:590-597.
27. Quataert SA, Rittenhouse-Olson K, Kirch CS, et al. Assignment of weight-based antibody units for 13 serotypes to a human antipneumococcal standard reference serum, lot 89-S (f). Clin Diagn Lab Immunol. 2004;11:1064-1069.
28. Siber GR, Chang I, Baker S, et al. Estimating the protective concentration of anti-pneumococcal capsular polysaccharide antibodies. Vaccine. 2007;25:3816-3826.
29. World Health Organization. Pneumococcal conjugate vaccines. Recommendations for the production and control of pneumococcal conjugate vaccines. WHO Tech Rep Serv. 2005;927(Annex 2):64-98.
30. Feavers I, Knezevic I, Powell M, et al.; WHO Consultation on Serological Criteria for Evaluation and Licensing of New Pneumococcal Vaccines. Challenges in the evaluation and licensing of new pneumococcal vaccines, 7-8 July 2008, Ottawa, Canada. Vaccine. 2009;27:3681-3688.
31. World Health Organization. Pneumococcal conjugate vaccines WHO position paper - 2012. Wkly Epidemiol Rec. 2012;87:129-144.
32. Shao PL, Lu CY, Chang LY, et al. Safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in Taiwanese infants. J Formos Med Assoc. 2004;103:613-617.
33. Shao PL, Lu CY, Chang LY, et al. Safety and immunogenicity of heptavalent pneumococcal conjugate vaccine booster in taiwanese toddlers. J Formos Med Assoc. 2006;105:542-549.
34. Kim NH, Lee J, Lee SJ, et al. Immunogenicity and safety of pneumococcal 7-valent conjugate vaccine (diphtheria CRM (197) protein conjugate; Prevenar) in Korean infants: differences that are found in Asian children. Vaccine. 2007;25:7858-7865.
35. Lee H, Nahm MH, Burton R, et al. Immune response in infants to the heptavalent pneumococcal conjugate vaccine against vaccine-related serotypes 6A and 19A. Clin Vaccine Immunol. 2009;16:376-381.
36. Rennels MB, Edwards KM, Keyserling HL, et al. Safety and immunogenicity of heptavalent pneumococcal vaccine conjugated to CRM197 in United States infants. Pediatrics. 1998;101(4 Pt 1):604-611.
37. Käyhty H, Ahman H, Eriksson K, et al. Immunogenicity and tolerability of a heptavalent pneumococcal conjugate vaccine administered at 3, 5 and 12 months of age. Pediatr Infect Dis J. 2005;24:108-114.